Sylke Haal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1277890/publications.pdf

Version: 2024-02-01

9	139	7	9
papers	citations	h-index	g-index
9	9	9	138
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Risk Factors for Symptomatic Gallstone Disease and Gallstone Formation After Bariatric Surgery. Obesity Surgery, 2022, 32, 1270-1278.	2.1	16
2	Factors associated with adherence to ursodeoxycholic acid or placebo in patients after bariatric surgery. Surgery for Obesity and Related Diseases, 2022, , .	1.2	2
3	Antibiotic Therapy of 3ÂDays May Be Sufficient After Biliary Drainage for Acute Cholangitis: A Systematic Review. Digestive Diseases and Sciences, 2021, 66, 4128-4139.	2.3	8
4	Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 993-1001.	8.1	31
5	Risk Factors for Cholecystectomy After Laparoscopic Roux-En-Y Gastric Bypass. Obesity Surgery, 2020, 30, 507-514.	2.1	15
6	Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: statistical analysis plan for a randomised controlled trial (UPGRADE trial). Trials, 2020, 21, 676.	1.6	9
7	Antimicrobial therapy of 3Âdays or less is sufficient after successful ERCP for acute cholangitis. United European Gastroenterology Journal, 2020, 8, 481-488.	3.8	13
8	Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: study protocol for a randomized controlled trial (UPGRADE trial). BMC Gastroenterology, 2017, 17, 164.	2.0	38
9	Stent patency in patients with distal malignant biliary obstruction receiving chemo(radio)therapy. Endoscopy International Open, 2017, 05, E1035-E1043.	1.8	7